ScoreWhy is Concord Biotech Ltd ?
1
Poor long term growth as Operating profit has grown by an annual rate -0.34% of over the last 5 years
2
The company has declared Negative results for the last 3 consecutive quarters
- ROCE(HY) Lowest at 23.48%
- PBT LESS OI(Q) At Rs 79.46 cr has Fallen at -15.9% (vs previous 4Q average)
- PAT(Q) At Rs 66.90 cr has Fallen at -17.4% (vs previous 4Q average)
3
With ROE of 17.7, it has a Very Expensive valuation with a 6.7 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -23.38%, its profits have fallen by -3.5%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -23.38% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Concord Biotech for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Concord Biotech
-23.38%
-0.60
38.83%
Sensex
-3.74%
-0.28
13.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.26%
EBIT Growth (5y)
-0.34%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.66
Tax Ratio
24.86%
Dividend Payout Ratio
24.63%
Pledged Shares
0
Institutional Holding
17.02%
ROCE (avg)
29.08%
ROE (avg)
19.17%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
39
Industry P/E
35
Price to Book Value
6.70
EV to EBIT
32.20
EV to EBITDA
27.11
EV to Capital Employed
7.95
EV to Sales
10.28
PEG Ratio
NA
Dividend Yield
0.91%
ROCE (Latest)
24.99%
ROE (Latest)
17.73%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-11What is not working for the Company
ROCE(HY)
Lowest at 23.48%
PBT LESS OI(Q)
At Rs 79.46 cr has Fallen at -15.9% (vs previous 4Q average
PAT(Q)
At Rs 66.90 cr has Fallen at -17.4% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is not working for Concord Biotech
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 79.46 cr has Fallen at -15.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 94.49 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 66.90 cr has Fallen at -17.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 80.99 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
